EA202091260A1 - Новые пиперидинильные производные в качестве ингибиторов убиквитин-специфической протеазы 7 - Google Patents

Новые пиперидинильные производные в качестве ингибиторов убиквитин-специфической протеазы 7

Info

Publication number
EA202091260A1
EA202091260A1 EA202091260A EA202091260A EA202091260A1 EA 202091260 A1 EA202091260 A1 EA 202091260A1 EA 202091260 A EA202091260 A EA 202091260A EA 202091260 A EA202091260 A EA 202091260A EA 202091260 A1 EA202091260 A1 EA 202091260A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ubikvitin
inhibitors
specific protease
piperidinyl derivatives
new piperidinyl
Prior art date
Application number
EA202091260A
Other languages
English (en)
Inventor
Андраш Кочи
Чаба Вебер
Аттила Вашаш
Арпад Кишш
Балаж Мольнар
Агнеш Штрофек
Вилибальд Кун
Джеймс Брук Мюррей
Альба Масьяс
Элоди Левкович
Майя Шанрион
Лиза Иваншитц
Оливье Женест
Original Assignee
Ле Лаборатуар Сервье
Верналис (Р&Д) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ле Лаборатуар Сервье, Верналис (Р&Д) Лимитед filed Critical Ле Лаборатуар Сервье
Publication of EA202091260A1 publication Critical patent/EA202091260A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Соединения формулы (I)где R, R, R, B, W, Z, m и n являются такими, как определено в описании. Соединения настоящего изобретения обладают проапоптотическими и/или антипролиферативными свойствами, что позволяет их применение при патологиях, в которые вовлечен дефект апоптоза, как, например, для лечения злокачественного новообразования и иммунопатологических и аутоиммунных заболеваний.
EA202091260A 2017-11-29 2018-11-28 Новые пиперидинильные производные в качестве ингибиторов убиквитин-специфической протеазы 7 EA202091260A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1761338 2017-11-29
PCT/EP2018/082766 WO2019105963A1 (en) 2017-11-29 2018-11-28 New piperidinyl derivatives as inhibitors of ubiquitin specific protease 7

Publications (1)

Publication Number Publication Date
EA202091260A1 true EA202091260A1 (ru) 2020-09-07

Family

ID=62091951

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091260A EA202091260A1 (ru) 2017-11-29 2018-11-28 Новые пиперидинильные производные в качестве ингибиторов убиквитин-специфической протеазы 7

Country Status (17)

Country Link
US (1) US11332472B2 (ru)
EP (1) EP3717482A1 (ru)
JP (1) JP2021504388A (ru)
KR (1) KR20200094176A (ru)
CN (1) CN111542524A (ru)
AR (1) AR113846A1 (ru)
AU (1) AU2018377976A1 (ru)
BR (1) BR112020010547A2 (ru)
CA (1) CA3083320C (ru)
EA (1) EA202091260A1 (ru)
IL (1) IL274737A (ru)
MA (1) MA51202A (ru)
MX (1) MX2020005500A (ru)
RU (1) RU2020120043A (ru)
SG (1) SG11202004631RA (ru)
TW (1) TW201925202A (ru)
WO (1) WO2019105963A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113087724B (zh) * 2020-01-08 2024-01-19 四川科伦博泰生物医药股份有限公司 异噻唑并嘧啶酮类化合物，包含其的药物组合物及其用途
CN113087718B (zh) * 2020-01-09 2024-02-09 四川科伦博泰生物医药股份有限公司 噻吩并嘧啶酮类化合物及其医药应用
CN112047933B (zh) * 2020-10-15 2022-06-14 郑州大学 喹唑啉酮类usp7抑制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41291A (fr) * 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
TWI698436B (zh) * 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
FR3052452B1 (fr) 2016-06-10 2018-06-22 Les Laboratoires Servier Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
RU2020120043A (ru) 2021-12-29
BR112020010547A2 (pt) 2020-10-27
MX2020005500A (es) 2020-08-31
IL274737A (en) 2020-07-30
TW201925202A (zh) 2019-07-01
US11332472B2 (en) 2022-05-17
AU2018377976A1 (en) 2020-06-04
CA3083320A1 (en) 2019-06-06
WO2019105963A1 (en) 2019-06-06
KR20200094176A (ko) 2020-08-06
MA51202A (fr) 2020-10-07
EP3717482A1 (en) 2020-10-07
SG11202004631RA (en) 2020-06-29
US20200407363A1 (en) 2020-12-31
AR113846A1 (es) 2020-06-17
CN111542524A (zh) 2020-08-14
JP2021504388A (ja) 2021-02-15
CA3083320C (en) 2022-08-16

Similar Documents

Publication Publication Date Title
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
CY1124046T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
EA201992235A1 (ru) Синтез ингибитора mcl-1
CY1120969T1 (el) Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης
CY1122314T1 (el) Κυκλοπροπυλαμινες ως αναστολεις lsd1
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
EA201790271A1 (ru) Ингибиторы гликозидазы
EA202092441A1 (ru) Новые гетероциклические производные, применимые в качестве ингибиторов shp2
EA201991198A1 (ru) АМИНОТИАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
CY1119678T1 (el) Πυριμιδινονες ως αναστολεις τελεστη χια
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
EA201892147A1 (ru) Бициклические соединения
EA201991197A1 (ru) БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201892450A1 (ru) Ароматические сульфонамидные производные
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
CY1120846T1 (el) 2-αμινο-6-(διφθορομεθυλ)-5,5-διφθορο-6-φαινυλ-3,4,5,6-τετραϋδροπυριδινες ως αναστολεις bace1
EA202091260A1 (ru) Новые пиперидинильные производные в качестве ингибиторов убиквитин-специфической протеазы 7
EA201990400A1 (ru) Соединения и композиции и их применение
EA201891586A1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
EA201891644A1 (ru) Антибактериальные соединения и их применение
CY1120034T1 (el) Παραγωγα 5-βενζυλισοκινολεϊνης για την θεραπεια καρδιαγγειακων ασθενειων
EA202190475A1 (ru) Мини-gde для лечения гликогеноза iii типа
EA201892051A1 (ru) Фармацевтические композиции для лечения злокачественного новообразования